Contrast Enhanced Ultrasound for Renal Obstruction

Description

This research is studying Definity ultrasound contrast agent, which is already approved by the Food and Drug Administration (FDA) for the ultrasound evaluation of the liver and heart. This research will investigate the ability to use ultrasound imaging with ultrasound contrast agents to evaluate kidney obstruction. Eligible participants that are enrolled will have two visits (one before and one after the planned surgery to relieve the kidney obstruction).

Conditions

Kidney; Obstruction, Renal Obstruction

Talk to us

Study Overview

On this page

Study Details

Study overview

This research is studying Definity ultrasound contrast agent, which is already approved by the Food and Drug Administration (FDA) for the ultrasound evaluation of the liver and heart. This research will investigate the ability to use ultrasound imaging with ultrasound contrast agents to evaluate kidney obstruction. Eligible participants that are enrolled will have two visits (one before and one after the planned surgery to relieve the kidney obstruction).

Contrast Enhanced Ultrasound for Renal Obstruction

Contrast Enhanced Ultrasound for Renal Obstruction

Condition
Kidney; Obstruction
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Unilateral renal obstruction confirmed by Nuclear Medicine MAG3 Dynamic Renal Scan (diuretic t (time) ½ \>20 minutes)
  • * Obstructed kidney with differential function \>15% confirmed by Nuclear Medicine Mercaptoacetyltriglycine (MAG3) Dynamic Renal Scan within less or equal (\<=) 6 months from enrollment
  • * Patient has elected to move forward with pyeloplasty or proximal ureteroureterostomy to correct the obstruction
  • * Solitary kidney
  • * Any abnormalities of contralateral collecting system (for example (e.g.) hydronephrosis, renal calculi, duplicated collecting system)
  • * Known vesicoureteral reflux
  • * Ureteral stent in place in the obstructive kidney
  • * Patients without a Nuclear Medicine MAG3 Dynamic Renal Scan
  • * Previous history of hypersensitivity to Ultrasound Contrast Agents or Definity (perflutren lipid microspheres))
  • * Previous sensitivity to polyethylene glycol
  • * Pregnant or breastfeeding females
  • * Body mass index (BMI) \>=40 without prior ultrasound confirming ability to adequately visualize the kidneys (Elevated BMI is known to decrease ability to image the kidneys)
  • * Global renal function with a Glomerular Filtration Rate (GFR) \<30 (chronic kidney disease Stage 4 \& 5 excluded)
  • * Unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias, presence of a cardiac shunt)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan,

Sapan N Ambani, MD, PRINCIPAL_INVESTIGATOR, University of Michigan

Study Record Dates

2024-12